The understanding of LDD’s molecular pathogenesis, particularly its association with germline PTEN mutations and dysregulation of the PI3K/AKT/mTOR pathway, has opened avenues for targeted pharmacological interventions. The gene discussed is MTOR; the disease is Lhermitte-Duclos disease.